

Supplemental Table 1. Univariate Analysis of Overall Survival after Surgical Therapy for Lung Cancer

Level	Overall survival, mo		
	Hazard Ratio	95%CI	P-value
Facility type			
Academic/Research Program	0.79	0.77-0.82	< 0.001
Comprehensive Community Cancer Program	0.86	0.84-0.89	< 0.001
Community Cancer Program/Other	-	-	-
Sex			
Male	1.44	1.41-1.46	< 0.001
Female	-	-	-
Race/ethnicity			
Other	0.91	0.78-1.05	0.183
Hispanic	0.90	0.85-0.96	0.001
Asian	0.80	0.74-0.86	< 0.001
Black	1.01	0.97-1.04	0.625
White	-	-	-
Age	1.03	1.03-1.03	< 0.001
Insurance			
Not Insured	1.31	1.23-1.41	< 0.001
Govt. Insurance	1.55	1.52-1.58	< 0.001
Private Insurance	-	-	-
Income			
< \$30,000	1.26	1.22-1.29	< 0.001
\$30,000 - \$34,999	1.19	1.16-1.22	< 0.001
\$35,000 - \$45,999	1.12	1.10-1.15	< 0.001
\$46,000 +	-	-	-


Education			
>=29%	1.23	1.20-1.26	< 0.001
20-28.9%	1.16	1.14-1.19	< 0.001
14-19.9%	1.12	1.09-1.15	< 0.001
< 14%	-	-	-
Urban/rural: rural	1.18	1.11-1.25	< 0.001
Setting			
Urban	1.10	1.08-1.13	< 0.001
Metro Area	-	-	-
Charlson/Deyo score			
2+	1.50	1.46-1.54	< 0.001
1	1.17	1.15-1.19	< 0.001
0	-	-	-
Analytic stage			
IV	3.25	3.13-3.37	< 0.001
III	2.17	2.12-2.22	< 0.001
II	1.69	1.65-1.73	< 0.001
I	-	-	-
Radiation before surgery			
Yes	1.44	1.39-1.50	< 0.001
No	-	-	-

Primary tumor site			
Tracheobronchial tree or hilum	1.11	1.02-1.22	0.017
Left upper lobe	1.07	1.05-1.10	< 0.001
Left lower lobe	1.09	1.06-1.12	< 0.001
Right middle lobe	0.85	0.82-0.89	< 0.001
Right lower lobe	1.12	1.09-1.15	< 0.001
Overlapping lesion	1.41	1.33-1.50	< 0.001
Not specified	1.48	1.40-1.56	< 0.001
Right upper lobe	-	-	-
Histology			
Unknown histology	1.31	1.26-1.35	< 0.001
Other tumors [†]	0.38	0.36-0.40	< 0.001
Large cell	1.38	1.32-1.43	< 0.001
Squamous cell	1.27	1.25-1.30	< 0.001
Adenosquamous	1.36	1.30-1.44	< 0.001
Adenocarcinoma	-	-	-
Grade			
Unknown	1.27	1.22-1.32	< 0.001
4	2.14	2.02-2.26	< 0.001
3	1.98	1.92-2.05	< 0.001
2	1.64	1.59-1.70	< 0.001
1	-	-	-
Tumor size, cm	1.02	1.02-1.02	< 0.001
Surgical procedure			
Pneumonectomy	1.16	1.12-1.20	< 0.001
Lobectomy	0.68	0.66-0.70	< 0.001
Segmental resection, including lingulectomy	0.80	0.75-0.84	< 0.001
Wedge resection/less than one lobe			-

Positive surgical margins			
Yes	2.23	2.17-2.30	< 0.001
No	-	-	-
Scope of regional LN surgery			
No regional LN surgery	1.42	1.38-1.46	< 0.001
Regional LN surgery	-	-	-
Regional LN positive			
Yes	1.84	1.81-1.88	< 0.001
No	-	-	-
Regional LN examined			
>9	0.85	0.83-0.87	< 0.001
7-9	0.80	0.78-0.83	< 0.001
4-6	0.82	0.79-0.84	< 0.001
0-3	-	-	-

[†]Including, but not restricted to spindle cell carcinoma, mucoepidermoid malignancies, neuroendocrine, and mixed malignant tumors; LN: Lymph Node


Supplementary Figure 1



AJCC Clinical Stage Group — I — II — III — IV

AJCC Clinical Stage Group	No. of Subject	Event	Censored	Median Survival (95% CI)
I	24586	12422 (51%)	12164 (49%)	74.6 (73, 75.6)
II	4644	2993 (64%)	1651 (36%)	40.3 (38.3, 43.2)
III	6607	4601 (70%)	2006 (30%)	31 (29.4, 32.5)
IV	2187	1790 (82%)	397 (18%)	16.3 (14.8, 17.7)

Supplementary Figure 2



AJCC Pathologic Stage Group	No. of Subject	Event	Censored	Median Survival (95% CI)
I	51216	24417 (48%)	26799 (52%)	80.3 (79.5, 81.4)
II	13369	8696 (65%)	4673 (35%)	41.3 (40, 42.6)
III	11987	8775 (73%)	3212 (27%)	28.9 (28, 30)
IV	3253	2675 (82%)	578 (18%)	17.2 (16, 18.1)